CERTAINTY (A Cellular Immunotherapy Virtual Twin for Personalised Cancer Treatment) is a four-year research project funded by the European Union under Grant Agreement number 101136379. It brings together 17 partners from across Europe, coordinated by Fraunhofer (Germany), with a shared mission to personalise cancer care.
The project is focused on developing a virtual twin for patients undergoing CAR T cell therapy, a pioneering form of cancer treatment. By creating a computational model that mirrors individual patients, CERTAINTY aims to support doctors and patients with insights that may guide treatment decisions and improve outcomes.
Our goal is to contribute to a more informed, data-driven approach to cancer therapy, enhancing the effectiveness and safety of personalised treatments through cutting-edge digital tools.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- South Jordan.
Certainty Questions
Certainty's website is https://www.certainty-virtualtwin.eu
Certainty's LinkedIn profile is https://www.linkedin.com/company/certainty-vt
Certainty's industry is
Biotechnology Research
Certainty's top competitors are
Teach4md,
Simcor,
Dgkl Kongress 2024,
Crids/nadi,
Edith-Csa,
Healthtree Foundation,
Fraunhofer Izi,
Daisybio,
Cancerdatanet Gmbh (Acquired By Trinetx),
Leistungszentrum Einzelzelltechnologien Lz-Ezt.
Certainty's categories are Biotechnology Research
Certainty's founding year is 2023
